
Bristol Myers Squibb bags European Commission approval for Opdivo combo in lung cancer treatment
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell …